M&A / Deals Lilly boosts ADC portfolio with CrossBridge Bio deal BioPharma DiveWorth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.M&A / DealsOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) BioPharma Dive Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly investing billions to prepare for overseas oral GLP-1 launchesNext: With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
